Please login to the form below

Not currently logged in
Email:
Password:

CHMP gives negative opinion for Cladribine

European regulator rejects Merck's oral treatment for relapsing-remitting MS

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a negative opinion regarding the marketing authorisation application (MAA) for Merck's cladribine (leustatin) tablets as a treatment for relapsing-remitting multiple sclerosis (MS).

The CHMP stated that, based on currently available data, it does not believe that the benefits of cladribine outweigh its risks. Of particular concern to the regulator were the cancer cases witnessed during clinical trials of cladribine and the damping down effect it has on the immune system.

The negative opinion came just days after the US Food and Drug Administration (FDA) approved Novartis' MS pill Gilenya (fingolimod) as a first line treatment for patients with relapsing forms of MS. This decision places Novartis ahead of Merck in the race to bring the first oral treatment to market. However, Gilenya is still under review and yet to be approved in Europe.

In response to the CHMP's announcement, Merck has affirmed its committment to making cladribine tablets available to MS patients in Europe. The company said it is evaluating all options to gain approval in the European Union, including a potential appeal to request re-examination of the submission by the CHMP, in accordance with the current European regulatory legislation. 

Cladribine tablets were approved in Australia and Russia recently as a treatment of relapsing-remitting MS under the trade name Movectro and are under regulatory review in other countries, including the US where the application has been granted priority review by the FDA.

27th September 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics